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P rolactin (PRL) is a polypeptide hormone that is phylogenetically well-conserved but elicits various 
species-dependent functions [1 , 2].  PRL is related to the 
regulation of osmotic pressure in fish and amphibians,  
fat retention in reptiles and birds,  and glucose-lipid 
metabolism,  bone homeostasis and development of the 
mammary gland in mammals [3].
In humans,  PRL secretion is regulated in an inhibi-
tory manner by dopaminergic neurons that project 
from the hypothalamus to PRL-producing cells in the 
anterior pituitary gland [4].  Since dopaminergic actions 
are mainly mediated by dopaminergic D2 receptors 
(D2R),  various agents that bind D2R can affect serum 
PRL levels [5].  In a clinical setting,  hyperprolactinemia 
is considered in cases of galactorrhea,  infertility and 
sexual dysfunction [5-7].
Other causes of hyperprolactinemia include PRL-
producing pituitary adenomas (prolactinomas),  hypo-
thyroidism and chronic kidney disease [8 , 9].  In addi-
tion,  PRL receptors have been considered as therapeutic 
targets for some cancers (e.g.,  prostate cancer and breast 
cancer) and autoimmune diseases (e.g.,  rheumatoid 
arthritis and systemic lupus erythematosus) [10 , 11].  It 
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To clarify the relevance of prolactin (PRL) to clinical parameters in patients who visited our general medicine 
department,  medical records of 353 patients in whom serum PRL levels were measured during the period from 
2016 to 2018 were retrospectively reviewed.  Data for 140 patients (M/F: 42/98) were analyzed after excluding 
patients lacking detailed records and patients taking dopaminergic agents.  Median serum PRL levels were sig-
nificantly lower in males than females: 6.5 ng/ml (IQR: 4.2-10.3) versus 8.1 ng/ml (5.9-12.9),  respectively.  
Pain and general fatigue were the major symptoms at the first visit,  and past histories of hypertension and dys-
lipidemia were frequent.  Male patients with relatively high PRL levels (≥ 10 ng/ml) had significantly lower levels 
of serum albumin and significantly higher levels of serum LDH than those with low PRL (< 10 ng/ml).  There 
were significant correlations of male PRL level with the erythrocyte sedimentation rate (R= 0.62),  serum LDH 
level (R= 0.39) and serum albumin level (R= −0.52),  while the level of serum CRP (R= 0.33) showed an insignif-
icant but weak positive correlation with PRL level.  Collectively,  these results show that PRL levels had gen-
der-specific relevance to various clinical factors,  with PRL levels in males being significantly related to inflam-
matory status.
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has also been shown that hyperprolactinemia in some 
patients is related to psychiatric conditions such as 
depression and anxiety [12 , 13].  Given that several 
pathophysiological functions related to PRL have 
recently been uncovered,  the clinical measurement of 
serum PRL levels could become more widely adopted.
In the present study,  we retrospectively investigated 
the relevance of serum PRL levels to various clinical 
parameters in patients who visited a general medicine 
department with various symptoms at the first visits.  It 
was of interest that there were significant correlations 
between serum PRL levels and inflammatory indexes,  
particularly in male patients.  The present findings may 
expand the utility of PRL measurement in serum to a 
gender-specific inflammatory index.
Patients and Methods
Study design. We screened the medical records 
of 353 patients whose serum PRL levels were measured 
between January 2016 and December 2018 at the 
Department of General Medicine,  Okayama University 
Hospital.  Of those patients,  194 patients who did not 
have the required laboratory data and clinical informa-
tion regarding self-rating depression scale (SDS) and 
frequency scale for symptoms of gastroesophageal 
reflux disease (FSSG) and 19 patients who were admin-
istered drugs that affect D2R were excluded.  Among 
the 213 excluded cases,  128 cases were treated for 
hypothalamo- and pituitary-related disorders,  and 103 
of those 128 cases were examined in regular checkups 
for previously diagnosed pituitary tumors,  while the 
other 25 cases had pituitary dysfunction from an auto-
immune condition or unknown causes other than 
tumorous lesions.  As a result,  140 patients were 
included in the present analysis.  The decision to exam-
ine serum PRL levels was made by individual physicians 
for clinical purposes when hypothalamo- and/or pitu-
itary-related symptoms were suspected.  Patients with 
pituitary prolactinomas were not included in the pres-
ent study.  Data for other biochemical parameters were 
obtained within 1 week after measurement of PRL.  
Blood tests were performed in cases with adequate 
insurance coverage.  Information on this retrospective 
study was disclosed on our hospital website and posted 
on a hospital wall,  and a contact point was provided for 
participants who wished to opt-out.  This study was 
approved by the Ethical Committee of Okayama 
University Hospital (No. 1902-005) and adhered to the 
Declaration of Helsinki.
Analysis of clinical parameters. Information on 
the patients’ initial symptoms and past histories was 
obtained from hospital medical records.  Each patient 
had multiple manifestations and diagnosed diseases.  
We obtained information on all of them,  and those 
common to two or more patients were analyzed.   Age,  
body mass index (BMI),  SDS and FSSG were also eval-
uated.   Blood biochemical data included the following 
parameters: white blood cells,  red blood cells,  hemo-
globin,  hematocrit and platelets for blood cell counts;  
total bilirubin,  total protein,  albumin,  aspartate ami-
notransferase (AST),  alanine aminotransferase (ALT),  
alkaline phosphatase (ALP),  lactate dehydrogenase 
(LDH),  γ-glutamyl transpeptidase (γGTP),  creatinine 
and estimated glomerular filtration rate (eGFR) for liver 
and renal functions; C-reactive protein (CRP),  eryth-
rocyte sedimentation rate in one hour (ESR),  ferritin,  
immunoglobulin G (IgG),  immunoglobulin A (IgA),  
immunoglobulin M (IgM),  50% hemolytic unit of com-
plement (CH50) and fibrinogen for inflammatory 
markers; and hemoglobin A1c (HbA1c),  total choles-
terol,  uric acid,  adrenocorticotropic hormone (ACTH),  
cortisol,  follicle-stimulating hormone (FSH),  growth 
hormone (GH),  thyroid-stimulating hormone (TSH),  
free thyroxine (FT4),  and ratio of TSH/FT4 and total 
testosterone for endocrine and metabolic markers.  The 
levels of the above-mentioned factors were determined 
using an auto-analyzer system at the Central Laboratory 
of Okayama University Hospital.  PRL levels were deter-
mined by a fluorescence enzyme immunoassay or che-
miluminescence enzyme immunoassay using a com-
mercially available kit (Tosoh Corporation,  Tokyo).  
The accuracy and correlation of both assay systems were 
validated previously.
Statistical analysis. All statistical analyses were 
performed with EZR,  version 1.40 (Saitama Medical 
Center,  Jichi Medical University,  Saitama,  Japan),  
which is a graphical user interface for R (The R Founda-
tion for Statistical Computing,  Vienna,  Austria) [14].  
More precisely,  it is a modified version of R com-
mander designed to add statistical functions frequently 
used in biostatistics.  Continuous measurements were 
tested by the Mann-Whitney U test or Spearman’s rank 
correlation coefficient,  since the serum PRL levels did 
not follow a normal distribution in either gender 
(p < 0.01 by the Shapiro-Wilk normality test).  All tests 
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were two-sided,  and p values of less than 0.05 were con-
sidered to indicate statistical significance.
Results
Patients’ characteristics and distribution of serum 
PRL levels. The 140 patients analyzed in the present 
study included 42 males (30%) and 98 females (70%).  
As shown in Fig. 1A,  the mean age of males was 
48.5 ± 18.4 years and that of females was 44.7 ± 19.4 
years.  As shown in the left panel of Fig. 1B,  the serum 
PRL level in male patients was significantly lower than 
that in female patients.  The median PRL level in male 
patients was 6.5 (interquartile range (IQR): 4.2-10.3) 
ng/ml and the median level in female patients was 8.1 
(IQR: 5.9-12.9) ng/ml (Fig. 1B,  left).  We also stratified 
female patients according to their age at the time of 
examination in order to account for the potential effects 
of menopause,  which in Japanese is considered to occur 
at around 50 years of age [15].  As shown in the middle 
panel of Fig. 1B,  among patients aged < 50 years,  the 
serum PRL level was significantly higher in females 
than males; however,  no gender-dependent difference 
in serum PRL levels was observed in patients aged ≥ 50 
years (Fig. 1B,  right).  As shown in Fig. 1C,  the correla-
tion between serum PRL levels and age was not signifi-
cant in male patients (R= 0.17,  p= 0.30).  Also,  in female 
patients,  the correlation of serum PRL levels with age 
was not significant in either the group aged < 50 years 
(R = 0.025,  p = 0.85) or the group aged ≥ 50 years 
(R = 0.037,  p = 0.83) (Fig. 1D).
The patients’ initial symptoms and their past histo-
ries are shown in Fig. 2.  The most frequent symptom 
was pain (26.3%,  42 of 160 symptoms),  including 
somatic pain (20.6%,  33/160) and headache (6.9%,  
11/160),  followed by general fatigue (23.1%,  37/160),  
October 2020 Prolactin as an Inflammatory Marker 383
C
R=0.17, P=0.30 (n=42)
P
R
L
 (
n
g
/m
l)
Age (years)
0
10
20
30
10 30 50 70 90
Male patients Female patientsD
R=0.025, P=0.85 (n=61)
Age (years)
P
R
L
 (
n
g
/m
l)
0
20
40
60
80
100
120
140
50 60 70 80 90
0
20
40
60
80
100
120
140
10 20 30 40 50
R=0.037, P=0.83 (n=37)
Age (years)
A
A
g
e
n.s.
Male Female
P
R
L
 (
n
g
/m
l) ＊
B
Male Female
＊ n.s.
P
R
L
 (
n
g
/m
l)
Age<50 Age≥50
Male FemaleMale Female
All patients
100
90
80
70
60
50
40
30
20
10
0
140
120
100
80
60
40
20
0
140
120
100
80
60
40
20
0
140
120
100
80
60
40
20
0
Fig. 1　 Age- and gender-dependent distributions of serum PRL levels.  The age-dependent distribution (A) and serum PRL levels (B) are 
shown for each gender.  In each panel,  the upper horizontal line of the box is the 75th percentile,  the lower horizontal line of the box is the 
25th percentile,  the horizontal bar within the box is the median,  the upper horizontal bar outside the box is the maximum value within 1.5 
times the interquartile range,  and the lower horizontal bar outside the box is the minimum value within 1.5 times the interquartile range.  
Interrelationships between age and serum PRL levels in male (C) and female (D) patients are shown.  ＊p<0.05,  statistically significant 
difference between the indicated groups (B) and correlations between indicated factors (C and D).  n.s.,  not significant; PRL,  prolactin.
fever (11.3%,  18/160) and weight loss (8.8%,  14/160).  
These symptoms were predominant in female patients,  
with female ratios of 78.8% for various types of pain,  
78.4% for general fatigue,  83.3% for fever and 85.7% for 
weight loss (Fig. 2,  left).  The manifestations directly 
related to hyperprolactinemia included sexual dysfunc-
tion (1.9%,  3/160) in males and amenorrhea (2.5%,  
4/160) and hirsutism (1.3%,  2/160) in females (Fig. 2,  
left).  The most frequent past histories were hyperten-
sion (15.9%,  23 of 145 histories) and dyslipidemia 
(13.8%,  20/145) followed by upper gastrointestinal (GI) 
inflammation (9.7%,  14/145) and asthma (9.7%,  14/145) 
(Fig. 2,  right).  The female ratios were relatively high for 
upper GI inflammation (85.7%,  12/14) and hyperten-
sion (65.2%,  15/23).  In addition,  past histories possi-
bly related to hyperprolactinemia included mental dis-
orders (5.5%,  8/145),  brain tumors (4.8%,  7/145) and,  
in female cases,  polycystic ovary syndrome (PCOS;  
2.1%,  2/97) (Fig. 2,  right).  Regarding the mental condi-
tion of the patients,  the serum PRL level did not show a 
significant correlation with SDS in either of the gender 
groups (male: R = 0.030,  p = 0.85; female: R = −0.056,  
p = 0.58) (Table 1).
Relevance of serum PRL levels to inflammatory 
parameters. The patients were divided into 2 groups 
according to whether their serum PRL levels were 
higher or lower than 10 ng/ml (Fig. 3).  A comparison of 
the groups with relatively high (≥ 10 ng/ml) and low 
(< 10 ng/ml) serum PRL levels showed that the patients 
with high PRL levels had higher levels of ESR regardless 
of gender,  though the difference was not significant 
(Fig. 3A).  The group of male patients with relatively 
high PRL levels had a significantly lower level of serum 
albumin (Fig. 3B) but higher levels of LDH (Fig. 3C),  
whereas these trends were not found in female patients 
(Fig. 3A-C).  Of note,  as shown in Fig. 4,  significant 
correlations were observed between the serum PRL level 
and ESR (R = 0.62,  ＊＊p < 0.01; Fig. 4A) and between the 
serum levels of LDH (R = 0.39,  ＊p < 0.05; Fig. 4B) and 
albumin (R = −0.52,  ＊p < 0.01; Fig. 4C).  The serum PRL 
level also showed a weak positive correlation with CRP 
(R= 0.33,  p= 0.076) in male patients (Fig. 4D).  The male 
patients for whom results are shown in Fig. 4 included 2 
patients with hypothalamo- and pituitary-related dis-
eases in their past history (Fig. 2,  right).  One patient had 
undergone curative surgery for acromegaly without 
medication or hormone replacement therapy (HRT) 
and the other patient had been treated with HRT for 
hypopituitarism after surgery for craniopharyngioma.  
Even when these 2 patients were excluded from the 
analysis,  the significant relations remained between the 
serum PRL level and inflammatory markers in male 
patients (Fig. 4).  The statistics after exclusion of these 2 
cases were as follows: ESR: R = 0.65,  ＊＊p < 0.01; albu-
min: R=−0.53,  ＊＊p<0.01; LDH: R=0.35,  ＊p<0.05;  
and CRP: R = 0.30,  p = 0.12.  On the other hand,  in 
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Fig. 2　 Patientsʼ main initial symptoms and past histories.  The left panel shows patientsʼ main initial symptoms (total of 160 symptoms 
in 140 patients) and the right panel shows past histories (145 past histories for 140 patients).  Grey bars and white bars indicate the data for 
male and female patients,  respectively.  GI,  gastrointestinal; PCOS,  polycystic ovary syndrome.
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Table 1　 Correlations between serum PRL levels and clinical parameters
Male Female
Comparison with PRL
number R P values number R P values
Patientsʼ profile
Age 42 0.17 0.30 61 (<50 years) 0.03 0.85
37 (≥50 years) 0.04 0.83
BMI 42 －0.050 0.76 98 －0.17 0.10
SDS 42 0.030 0.85 98 －0.056 0.58
FSSG 42 0.021 0.90 94 －0.049 0.64
Blood cell count
White blood cell 36 0.18 0.29 91 －0.082 0.44
Red blood cell 36 －0.12 0.48 91 －0.018 0.87
Hemoglobin 36 －0.22 0.20 91 0.038 0.72
Hematocrit 36 －0.16 0.35 91 0.059 0.58
Platelet 36 －0.21 0.22 91 0.14 0.18
Liver and renal function
Total bilirubin 33 －0.047 0.80 87 0.040 0.72
Total protein 25 －0.31 0.13 64 －0.077 0.55
Albumin 34 －0.52 0.0015＊＊ 88 －0.11 0.33
AST 35 0.17 0.33 90 －0.068 0.53
ALT 35 －0.045 0.80 90 －0.040 0.71
ALP 35 0.058 0.74 88 －0.15 0.17
LDH 35 0.39 0.021＊ 88 －0.074 0.49
γGTP 33 0.053 0.77 84 －0.004 0.97
Creatinine 35 0.014 0.94 91 0.036 0.74
eGFR 35 －0.059 0.74 91 0.039 0.71
Inflammatory markers
CRP 29 0.33 0.076 83 －0.12 0.27
ESR 17 0.62 0.0074＊＊ 45 0.12 0.42
Ferritin 12 0.21 0.51 33 0.12 0.50
IgG 10 －0.037 0.92 38 0.025 0.88
IgA 10 0.35 0.33 33 0.040 0.83
IgM 10 －0.10 0.79 33 －0.013 0.94
CH50 8 0.64 0.09 31 －0.13 0.47
Fibrinogen 7 －0.56 0.19 24 －0.12 0.59
Endocrine and metabolic markers
HbA1c 24 0.16 0.46 67 －0.19 0.13
Total cholesterol 31 －0.056 0.76 76 －0.16 0.16
Uric acid 35 －0.089 0.61 87 －0.024 0.83
ACTH 33 0.19 0.29 72 －0.0069 0.95
Cortisol 33 0.21 0.25 74 0.11 0.37
FSH 38 0.16 0.32 51 (<50 years) －0.2 0.17
35 (≥50 years) －0.17 0.32
GH 36 －0.057 0.74 73 0.32 0.0062＊＊
TSH 36 0.40 0.015＊ 90 0.12 0.28
FT4 36 －0.34 0.044＊ 84 －0.060 0.59
TSH/FT4 36 0.45 0.0063＊＊ 84 0.14 0.21
Total teststerone 25 0.079 0.71 37 －0.036 0.83
＊＊P<0.01 and ＊P<0.05,  statistically significant between the indicated factors.
ACTH,  adrenocorticotropic hormone; ALP,  alkaline phosphatase; ALT,  alanine aminotransferase; AST,  aspartate aminotransferase;  
BMI,  body mass index; CH50,  50% hemolytic unit of complement; CRP,  C-reactive protein; eGFR,  creatinine and estimated glomerular filtration 
rate; ESR,  erythrocyte sedimentation rate in one hour; FSH,  follicle-stimulating hormone; FSSG,  frequency scale for the symptoms of gastroesopha-
geal reflux disease; FT4,  free thyroxine; γGTP,  γ-glutamyl transpeptidase; GH,  growth hormone; HbA1c,  hemoglobin A1c; IgA,  immunoglobulin 
A; IgG,  immunoglobulin G; IgM,  immunoglobulin M; LDH,  lactate dehydrogenase; PRL,  prolactin; SDS,  self-rating depression scale; TSH,  thyroid- 
stimulating hormone; Parentheses indicate patientsʼ age.
female patients,  serum PRL levels had no significant 
relevance to the levels of ESR (R = 0.12,  p = 0.42),  albu-
min (R = −0.11,  p = 0.33),  LDH (R = −0.074,  p = 0.49) or 
CRP (R = −0.12,  p = 0.27) (Table 1).
Interrelationships between serum PRL levels and 
other laboratory data. The PRL levels showed signif-
icant correlations with thyroid functions,  including 
TSH (R = 0.40,  ＊p < 0.05),  FT4 (R = −0.34,  ＊p < 0.05) 
and the TSH/FT4 ratio (R = 0.45,  ＊＊p < 0.01),  in male 
patients but not in female patients (Table 1).  There 
were no significant correlations between male PRL lev-
els and laboratory markers involved in the changes of 
ESR levels [16 , 17],  including age,  BMI,  hemoglobin,  
renal functions as determined by creatinine and eGFR,  
immunoglobulins including IgG,  IgA and IgM,  and 
fibrinogen,  as shown in Table 1.  Considering that 
menopause could affect serum FSH levels in female 
patients,  female patients were analyzed by stratifying 
them into two age groups of < 50 and ≥ 50 years for the 
correlation analysis between FSH and PRL.  No signifi-
cant correlation was found in either age group (age < 50 
years: R = −0.20,  p = 0.17; age ≥ 50 years: R = −0.17,  
p = 0.32) (Table 1).  In addition,  the serum PRL level 
was positively correlated with the serum GH level 
(R = 0.32,  ＊＊p < 0.01) only in female patients (Table 1).
Discussion
In the present study,  we found that PRL levels had 
gender-specific relevance to various clinical factors.  In 
general,  the PRL levels were lower in males than in 
females,  and pain and general fatigue were frequent 
manifestations of all the patients.  Past histories of 
hypertension and dyslipidemia were also frequent.  Of 
interest,  the serum PRL level in male patients was pos-
itively correlated with inflammatory indicators,  includ-
ing ESR and serum levels of LDH and CRP,  but was 
negatively correlated with the serum level of albumin,  
suggesting that PRL is functionally involved in various 
inflammatory reactions like a cytokine.  On the other 
hand,  female PRL levels were not correlated with such 
an inflammatory status.
In recent pathophysiological research on PRL,  much 
attention has been paid to inflammation,  especially 
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Fig. 3　 Trends of inflammatory marker levels in relation to serum PRL levels.  The patients were divided into two groups according to their 
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between the indicated factors.  CRP,  C-reactive protein; ESR,  erythrocyte sedimentation rate in one hour; LDH,  lactate dehydrogenase;  
n.s.,  not significant; PRL,  prolactin.
inflammation in autoimmune diseases [18].  A meta- 
analysis conducted by Wu et al.  revealed that the circu-
lating PRL level in patients with rheumatoid arthritis 
was significantly higher than that in control patients 
[19],  and the parameters for patients with higher circu-
lating PRL levels were Asian race,  age ≥ 50 years and 
ESR ≥ 25 mm/hour.  Increases in circulating PRL levels 
in patients with systemic lupus erythematosus [20] and 
multiple sclerosis [21] have also been shown by using 
meta-analyses.  In addition,  other autoimmune diseases 
such as polymyalgia rheumatica [22] and psoriatic 
arthritis [23 , 24] have been considered to have some 
relation to the levels of PRL,  although direct associa-
tions between such diseases and PRL activity have yet to 
be clarified.
Here,  we revealed a correlation between PRL and an 
inflammatory condition in male patients who visited 
our general medicine department.  It has been reported 
that acute inflammation upregulates PRL through an 
extra-pituitary mechanism,  while chronic inflamma-
tion induces PRL by both pituitary and extra-pituitary 
pathways [25 , 26].  ESR is a marker of inflammatory 
status,  particularly in the acute phase reactions seen in 
cases of infection,  autoimmune disease and cancer.  
ESR is the rate at which erythrocytes settle at the bot-
tom of a test tube in an anticoagulated blood sample,  
usually over a period of one hour.  Some molecules,  
such as fibrinogen and immunoglobulins,  that promote 
aggregation of erythrocytes can increase ESR [16].  
However,  an increase in ESR is also observed in 
patients with anemia,  renal failure,  or obesity,  in aged 
patients and in female patients [17].  In the present 
study,  serum PRL levels were not correlated with these 
factors that affect ESR.
Pain was the most frequent initial symptom in our 
patients.  A large proportion of the female patients 
(78.8%) complained of various types of pain.  It has been 
shown that serum PRL levels are elevated in patients 
with migraine [27] and in an experimental mouse 
model of postoperative pain [28].  As for the gender- 
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dependent difference in inflammatory reactions associ-
ated with PRL,  it has been suggested that PRL might act 
on inflammatory cells and signaling in different ways 
depending on the gender of the patient.  An elevated 
PRL level can modulate endocrine as well as immune 
responses,  and a positive feedback loop in which PRL 
stimulates the immune system while the products of 
immune cells stimulate further PRL secretion has been 
suggested [18 , 29].  In basic studies,  PRL and its recep-
tors have been shown to have some functional roles in 
neurogenesis,  neuroprotection and neural plasticity,  
particularly in the hippocampus [12].  From a clinical 
point of view,  hyperprolactinemia has been shown to be 
related to psychiatric disorders such as depression and 
anxiety [13].  In the present study,  the correlation 
between serum PRL level and SDS at the time of blood 
sampling was not significant in either gender,  although 
8 patients had past histories of psychiatric disorders 
such as depression,  bipolar disorders and eating disor-
ders.
It seems likely that at least some portion of the mod-
ulatory effects of PRL on endocrine and immune activ-
ities occur in a gender-dependent manner.  For instance,  
knockout of the PRL receptor has been shown to affect 
ovarian steroidogenesis in estrous female mice but to 
have no effect on the androgen level in male mice [30].  
In our study,  gender-dependent differences were found 
in the interrelationships between levels of serum PRL 
and other endocrine factors such as thyroid hormone 
and GH.  The pro-nociceptive actions of PRL also seem 
to be different in males and females,  since ablation of 
the PRL system caused a reduction of hypersensitivity 
to thermal stimuli in only female mice [28],  although 
the mechanisms contributing to the gender-dependent 
differences in pain sensitivity remain unclear.
There were some limitations of the present study.  
Serum PRL levels can be affected by circadian rhythm,  
stress,  medicines and the menstrual cycle.  Also,  this 
study was a retrospective single-center study in which 
sample sizes were relatively small and blood samplings 
were not always performed in the same period of time.  
Further studies,  including studies using a multi-center 
database,  will be needed to uncover the novel gen-
der-specific roles of PRL in the field of general medi-
cine.  Certainly,  it is reasonable to measure serum PRL 
levels when we suspect and/or are following-up hypo-
thalamo- and pituitary-related diseases.  However,  con-
sidering the novel interrelationships between PRL and 
inflammatory indexes,  attention must be given to latent 
inflammatory conditions even when examining patients 
with endocrine disorders.  In order to clarify the clinical 
details of the mutual interaction between PRL and 
inflammation,  a prospective study in age- and gender- 
matched cohorts is needed.
Collectively,  in male patients at our general medi-
cine department,  PRL levels were significantly related to 
inflammatory status.  Our findings suggest that there are 
gender-specific differences in the responses and roles of 
hormones and inflammation pathways in general med-
icine patients.
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